110 related articles for article (PubMed ID: 1671420)
1. Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.
Piwinski JJ; Wong JK; Green MJ; Ganguly AK; Billah MM; West RE; Kreutner W
J Med Chem; 1991 Jan; 34(1):457-61. PubMed ID: 1671420
[No Abstract] [Full Text] [Related]
2. Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine.
Kaminski JJ; Carruthers NI; Wong SC; Chan TM; Billah MM; Tozzi S; McPhail AT
Bioorg Med Chem; 1999 Jul; 7(7):1413-23. PubMed ID: 10465415
[TBL] [Abstract][Full Text] [Related]
3. Discovery and preliminary pharmacology of Sch 37370, a dual antagonist of PAF and histamine.
Billah MM; Egan RW; Ganguly AK; Green MJ; Kreutner W; Piwinski JJ; Siegel MI; Villani FJ; Wong JK
Lipids; 1991 Dec; 26(12):1172-4. PubMed ID: 1819703
[TBL] [Abstract][Full Text] [Related]
4. [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
Carceller E; Merlos M; Giral M; Balsa D; Almansa C; Bartrolí J; García-Rafanell J; Forn J
J Med Chem; 1994 Aug; 37(17):2697-703. PubMed ID: 7914928
[TBL] [Abstract][Full Text] [Related]
5. Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.
Piwinski JJ; Wong JK; Green MJ; Kaminski JJ; Colizzo F; Albanese MM; Ganguly AK; Billah MM; Anthes JC; West RE
Bioorg Med Chem Lett; 1998 Dec; 8(24):3469-74. PubMed ID: 9934454
[TBL] [Abstract][Full Text] [Related]
6. Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine.
Billah MM; Chapman RW; Egan RW; Gilchrest H; Piwinski JJ; Sherwood J; Siegel MI; West RE; Kreutner W
J Pharmacol Exp Ther; 1990 Mar; 252(3):1090-6. PubMed ID: 2319461
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationships of novel histamine H1 antagonists: indolylpiperidinyl benzoic acid derivatives.
Fonquerna S; Miralpeix M; Pagès L; Puig C; Cardús A; Antón F; Cárdenas A; Vilella D; Aparici M; Calaf E; Prieto J; Gras J; Huerta JM; Warrellow G; Beleta J; Ryder H
J Med Chem; 2004 Dec; 47(25):6326-37. PubMed ID: 15566302
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of [beta-(Aroylamino)ethyl]piperazines and -piperidines and [2-[(Arylamino)carbonyl]ethyl]piperazines, -pyrazinopyridoindoles, and -pyrazinoisoquinolines. A new class of potent H1 antagonists.
Saxena M; Agarwal SK; Patnaik GK; Saxena AK
J Med Chem; 1990 Nov; 33(11):2970-6. PubMed ID: 1977909
[TBL] [Abstract][Full Text] [Related]
9. Conformationally restricted analogs of histamine H1 receptor antagonists: trans and cis-1-benzyl-3-dimethylamino-6-phenylpiperidine.
Ahmed AE; Hanna PE; Grund VR
J Med Chem; 1976 Jan; 19(1):117-22. PubMed ID: 1535
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferase.
Cooper AB; Strickland CL; Wang J; Desai J; Kirschmeier P; Patton R; Bishop WR; Weber PC; Girijavallabhan V
Bioorg Med Chem Lett; 2002 Feb; 12(4):601-5. PubMed ID: 11844681
[TBL] [Abstract][Full Text] [Related]
11. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
[TBL] [Abstract][Full Text] [Related]
12. Optically active analogues of ebastine: synthesis and effect of chirality on their antihistaminic and antimuscarinic activity.
Zhang MQ; Walczynski K; Ter Laak AM; Timmerman H
Chirality; 1994; 6(8):631-41. PubMed ID: 7857774
[TBL] [Abstract][Full Text] [Related]
13. Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans.
Billah MM; Gilchrest HG; Eckel SP; Granzow CA; Lawton PJ; Radwanski E; Brannan MD; Affrime MB; Christopher JD; Richards W
Clin Pharmacol Ther; 1992 Aug; 52(2):151-9. PubMed ID: 1505150
[TBL] [Abstract][Full Text] [Related]
14. Optical isomers of rocastine and close analogues: synthesis and H1 antihistaminic activity of its enantiomers and their structural relationship to the classical antihistamines.
Sleevi MC; Cale AD; Gero TW; Jaques LW; Welstead WJ; Johnson AF; Kilpatrick BF; Demian I; Nolan JC; Jenkins H
J Med Chem; 1991 Apr; 34(4):1314-28. PubMed ID: 1673158
[TBL] [Abstract][Full Text] [Related]
15. Thienotriazolodiazepines as platelet-activating factor antagonists. Steric limitations for the substituent in position 2.
Walser A; Flynn T; Mason C; Crowley H; Maresca C; O'Donnell M
J Med Chem; 1991 Apr; 34(4):1440-6. PubMed ID: 2016721
[TBL] [Abstract][Full Text] [Related]
16. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
17. [Synthesis and pharmacological activities of cyclic analogues of fentanyl (author's transl)].
Klein W; Back W; Mutschler E
Arch Pharm (Weinheim); 1975 Dec; 308(12):910-6. PubMed ID: 4048
[No Abstract] [Full Text] [Related]
18. Piperidine-containing histamine H3 receptor antagonists of the carbamate series: the alkyl derivatives.
Lazewska D; Kieć-Kononowicz K; Elz S; Pertz HH; Stark H; Schunack W
Pharmazie; 2005 Jun; 60(6):403-10. PubMed ID: 15997826
[TBL] [Abstract][Full Text] [Related]
19. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist.
Corcóstegui R; Labeaga L; Innerárity A; Berisa A; Orjales A
Drugs R D; 2006; 7(4):219-31. PubMed ID: 16784247
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
Njoroge FG; Vibulbhan B; Rane DF; Bishop WR; Petrin J; Patton R; Bryant MS; Chen KJ; Nomeir AA; Lin CC; Liu M; King I; Chen J; Lee S; Yaremko B; Dell J; Lipari P; Malkowski M; Li Z; Catino J; Doll RJ; Girijavallabhan V; Ganguly AK
J Med Chem; 1997 Dec; 40(26):4290-301. PubMed ID: 9435898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
